- Home
- ALXO vs SNES Comparison
ALXO vs SNES Comparison
Compare ALXO & SNES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- SNES
- Stock Information
- Founded
- ALXO 2015
- SNES 2004
- Country
- ALXO United States
- SNES United States
- Employees
- ALXO N/A
- SNES N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- SNES Agricultural Chemicals
- Sector
- ALXO Health Care
- SNES Industrials
- Exchange
- ALXO Nasdaq
- SNES Nasdaq
- Market Cap
- ALXO 24.0M
- SNES 21.0M
- IPO Year
- ALXO 2020
- SNES 2016
- Fundamental
- Price
- ALXO $1.17
- SNES $4.60
- Analyst Decision
- ALXO Strong Buy
- SNES Strong Buy
- Analyst Count
- ALXO 6
- SNES 1
- Target Price
- ALXO $3.30
- SNES $10.00
- AVG Volume (30 Days)
- ALXO 1.7M
- SNES 147.2K
- Earning Date
- ALXO 08-12-2025
- SNES 08-07-2025
- Dividend Yield
- ALXO N/A
- SNES N/A
- EPS Growth
- ALXO N/A
- SNES N/A
- EPS
- ALXO N/A
- SNES N/A
- Revenue
- ALXO N/A
- SNES $2,093,000.00
- Revenue This Year
- ALXO N/A
- SNES $130.53
- Revenue Next Year
- ALXO N/A
- SNES $22.87
- P/E Ratio
- ALXO N/A
- SNES N/A
- Revenue Growth
- ALXO N/A
- SNES 36.89
- 52 Week Low
- ALXO $0.40
- SNES $1.30
- 52 Week High
- ALXO $2.59
- SNES $6.24
- Technical
- Relative Strength Index (RSI)
- ALXO 75.79
- SNES 46.41
- Support Level
- ALXO $0.80
- SNES $4.47
- Resistance Level
- ALXO $1.04
- SNES $4.88
- Average True Range (ATR)
- ALXO 0.11
- SNES 0.31
- MACD
- ALXO 0.05
- SNES -0.08
- Stochastic Oscillator
- ALXO 96.85
- SNES 22.16
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.